# 2025-04101: Sage pulls FDA nod for IV postpartum drug ZULRESSO

2025-04101, Sage Therapeutics, Inc.; Withdrawal of Approval of a New Drug Application for ZULRESSO (Brexanolone) Solution, 100 Milligrams/20 Milliliters, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-03-14, effective 2025-04-14; PRIA reads it as touching household money (as of 2026-09-30).

- Canonical: https://policyrisk.com/federal-register/2025-04101
- As of: 2026-09-30
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-04101
- Title: Sage Therapeutics, Inc.; Withdrawal of Approval of a New Drug Application for ZULRESSO (Brexanolone) Solution, 100 Milligrams/20 Milliliters
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 12162
- Published: 2025-03-14
- Effective: 2025-04-14
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-09-30

## In one line

Sage pulls FDA nod for IV postpartum drug ZULRESSO

## Summary

Sage Therapeutics has asked the FDA to withdraw approval for their drug ZULRESSO, which means it will no longer be sold after April 14, 2025. Patients and healthcare providers using ZULRESSO should plan for this change, but any existing stock can still be used until it runs out or expires. This move doesn’t stop Sage from applying again in the future if they want to.

## Abstract

The Food and Drug Administration (FDA or Agency) is withdrawing approval of a new drug application (NDA) for ZULRESSO (brexanolone) solution, 100 milligrams (mg)/20 milliliters (mL), held by Sage Therapeutics, Inc., 55 Cambridge Parkway, Cambridge, MA 02142 (Sage). Sage notified the Agency in writing that the drug product was no longer marketed and requested that the approval of the application be withdrawn.

## Effects PRIA read

- ZULRESSO approval withdrawn April 14, 2025: cost, medium. The FDA withdrew approval of NDA 211371 for ZULRESSO (brexanolone) solution, 100 mg/20 mL, effective April 14, 2025. This means ZULRESSO will no longer be a marketed, FDA‑approved drug after that date.
- Existing ZULRESSO stock can still be used: benefit, low. Any ZULRESSO (brexanolone) solution, 100 mg/20 mL, that is in inventory on April 14, 2025 may continue to be dispensed until the inventories are depleted or the drug products reach their expiration dates or otherwise become violative. Patients with existing prescriptions may still receive the drug…
- Sale or distribution prohibited after withdrawal: cost, low. After April 14, 2025, introducing or delivering ZULRESSO (brexanolone) solution, 100 mg/20 mL, into interstate commerce without an approved NDA will violate the Federal Food, Drug, and Cosmetic Act. Pharmacies, distributors, and others cannot lawfully sell or distribute this product after that date…
- Withdrawal is without prejudice to refiling: benefit, low. The withdrawal of approval for NDA 211371 was made under 21 CFR 314.150(c) and is without prejudice to refiling, so Sage Therapeutics may apply again in the future for approval of ZULRESSO. The company also waived its opportunity for a hearing.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-04101 on federalregister.gov](https://www.federalregister.gov/documents/2025/03/14/2025-04101/sage-therapeutics-inc-withdrawal-of-approval-of-a-new-drug-application-for-zulresso-brexanolone)
- [2025-04101 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-03-14/pdf/2025-04101.pdf)

## Related
- [Previous: 2025-04100, Proposed Extension of Information Collection Request Submitted for Public Comme…](https://policyrisk.com/federal-register/2025-04100)
- [Next: 2025-04106, Bausch & Lomb Incorporated, et al.; Withdrawal of Approval of Eight Abbreviated…](https://policyrisk.com/federal-register/2025-04106)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-04101 (as of 2026-09-30).
